Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
All are welcome to join an ECHO webinar on Tuesday June 21, 2022 (11 am – 12 pm EST) featuring Dr. Harry Rowland (CEO and Co-founder, Endotronix).
Dr. Rowland’s presentation entitled, “Insights from the Endotronix Journey: A PMA Medtech “Startup” Story”, will feature an overview of Endotronix, its technologies and the story behind its success. Endotronix is a medical technology company, delivering an integrated platform that provides comprehensive, reimbursable health management innovations for patients suffering from advanced heart failure. Please see attachment for more details.
Register in advance for this webinar: https://us02web.zoom.us/meeting/register/tZwkc-GrqD0sGtcnluN7KLI2wNtAxZ1kYIx9
ECHO is an entrepreneurship training program, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP), the University of Toronto component of the Ted Rogers Centre for Heart Research, and (ii) the Health Innovation Hub (H2i).